Write a five mark short note on Managmet of thyroid cancer Make it compatible, compact but high yielding. So that... I can easily remember and, uh, write it in a... Systematic way being a 2nd year resident. make it in a way its interesting and easy to learn visually and Create a high density, high yielding image based(generate image) Flashcard I can use Before exam to revise and remember all the important points regarding this short-note. but it should be in a way so its easy to understand and remember also use flowcharts or mindmaps in the response wherever possible dont use code

Reading File

Finding Sources

Reading File

Generating Image

A high-yield medical exam flashcard on "Management of Thyroid Cancer" for a 2nd year surgery resident. The card should be visually engaging, colorful, easy to remember, and organized like a mind map or visual flowchart. Include the following sections clearly labeled: 1. TYPES (color-coded boxes): PTC (Papillary - 80%), FTC (Follicular - 10%), MTC (Medullary - 5-10%), ATC (Anaplastic - 1%) 2. SURGICAL MANAGEMENT FLOWCHART: - Low-risk/small (<1cm): Lobectomy + Isthmusectomy - Most PTC/FTC: Total Thyroidectomy - Lymph nodes: Central neck dissection (CND) if N1a; Modified Radical Neck Dissection if N1b - MTC: Total thyroidectomy + routine CND - ATC: Palliative surgery only 3. POSTOP MANAGEMENT PILLARS (shown as 3 pillars/columns): - RAI (Radioiodine I-131): Low-risk = no RAI; Intermediate/High-risk = RAI ablation; Prepare with low-iodine diet + TSH stimulation - TSH Suppression: Levothyroxine; High-risk: TSH <0.1; Low-risk: TSH 0.5-2 - Surveillance: Thyroglobulin (Tg) levels + Neck USG every 6-12 months; Whole body RAI scan for high-risk 4. MTC SPECIAL BOX: RET mutation testing; Calcitonin marker; Screen for pheochromocytoma before surgery; MEN2A/2B associations; Vandetanib/Cabozantinib for metastatic disease 5. ATC SPECIAL BOX: Most aggressive; Multimodal = Surgery + XRT + Chemo; BRAF V600E mutation → Dabrafenib + Trametinib 6. TARGETED THERAPY BOX: RAI-refractory DTC → Sorafenib or Lenvatinib (multikinase inhibitors); MTC → Vandetanib/Cabozantinib; ATC BRAF+ → Dabrafenib + Trametinib 7. KEY MARKERS TABLE: PTC = Tg; MTC = Calcitonin + CEA; ATC = no useful marker 8. MNEMONIC at bottom: "TRST" = Total thyroidectomy → RAI → Suppression → Tg surveillance Use a dark blue/navy background with bright color-coded sections (yellow, green, orange, red, teal). Make it look like a premium exam revision card with clear visual hierarchy. Font should be bold and easy to read. Include small icons like a thyroid gland shape, radiation symbol for RAI, pill icon for suppression, and magnifying glass for surveillance.

Here is your complete high-yield short note + flashcard. Everything is structured to write fast in an exam and remember easily.

🩺 Management of Thyroid Cancer — High-Yield 5-Mark Short Note

QUICK ORIENTATION: Types at a Glance

THYROID CANCERS
     │
     ├── Differentiated (90%) ─── Well-differentiated, RAI-avid
     │       ├── Papillary (PTC) — 80% — spreads via LYMPHATICS
     │       └── Follicular (FTC) — 10% — spreads via BLOOD
     │
     ├── Medullary (MTC) — 5-10% — from C-cells, Calcitonin marker
     │
     └── Anaplastic (ATC) — 1% — most aggressive, worst prognosis

1. SURGICAL MANAGEMENT

Step 1 → Decide Extent of Surgery

Thyroid Cancer Confirmed
          │
    ┌─────┴──────┐
  Low Risk      High Risk
  (<1 cm, PTC)  (>1 cm, FTC, bilateral, ETE)
      │               │
  Lobectomy +    Total Thyroidectomy
  Isthmusectomy  (Near-total acceptable)

Step 2 → Lymph Node Management

Scenario	Surgery
N0 (no nodes palpable), PTC	Prophylactic CND optional (T3/T4 disease)
N1a (central nodes positive)	Central Neck Dissection (CND)
N1b (lateral nodes positive)	Modified Radical Neck Dissection (MRND)
MTC (all cases)	Routine CND always
ATC	Palliative resection only

Memory trick - "TOTAL for the following": T3/T4 tumor, >1cm, Bilateral, LN+, FTC/MTC/ATC

2. POSTOPERATIVE MANAGEMENT — THE "T-R-S-T" FRAMEWORK

After Total Thyroidectomy
          │
    ┌─────┼──────┐
    ↓     ↓      ↓
   RAI  SUPPRESS SURVEIL

☢️ RAI (Radioiodine I-131) Ablation

Who gets it? Based on ATA Risk Stratification:

LOW RISK        INTERMEDIATE RISK        HIGH RISK
(Unifocal PTC   (Microscopic ETE,         (Macroscopic ETE,
<1cm, no ETE,   aggressive histology,     distant mets, incomplete
no mets)        vascular invasion)        resection)
    │                   │                       │
 NO RAI          RAI ± (consider)           RAI ALWAYS

How to prep: Low-iodine diet + TSH stimulation (withhold T4 for 4 weeks OR give recombinant TSH - Thyrogen)
I-131 dose: 30 mCi for ablation; 100-200 mCi for metastases

💊 TSH Suppression (Levothyroxine)

Risk	Target TSH
High-risk	< 0.1 mIU/L (suppress fully)
Low-risk, remission	0.5 - 2.0 mIU/L (normal range)

🔍 Surveillance

Post-treatment Follow-up
         │
    ┌────┴────────┐
    ↓             ↓
Thyroglobulin    Neck USG
(Tg levels)     (every 6-12 months)
    │
  Rising Tg with negative USG → Whole Body RAI Scan
  Rising Tg + RAI negative → CT / PET-FDG scan

Key: Tg is the TUMOR MARKER for differentiated thyroid cancer (PTC + FTC). MTC uses Calcitonin + CEA.

3. MEDULLARY THYROID CANCER (MTC) — SPECIAL POINTS

MTC Diagnosed
    │
    ├── Check RET mutation (germline) → if +ve → screen family
    ├── Rule out PHEOCHROMOCYTOMA first (before surgery!)
    ├── Screen Ca2+ for hyperparathyroidism (MEN2A)
    │
    └── Surgery: Total thyroidectomy + Routine Central Neck Dissection
              (RAI is NOT useful — C-cells don't take up iodine)
    
Metastatic/Unresectable MTC:
    → Vandetanib or Cabozantinib (RET kinase inhibitors)

MEN Associations:

MEN 2A: MTC + Pheo + Parathyroid hyperplasia
MEN 2B: MTC + Pheo + Marfanoid + Mucocutaneous neuromas (codon 918)

4. ANAPLASTIC THYROID CANCER (ATC)

Almost always presents as Stage IVA/B/C - no Stage I/II/III
Treatment is mostly palliative + multimodal
BRAF V600E mutation (present in ~50%) → Dabrafenib + Trametinib (FDA approved, can "debulk" tumor for surgery)
XRT (external beam radiotherapy) + Doxorubicin (radiosensitizer)

5. TARGETED / NOVEL THERAPIES

Cancer Type	Drug	Mechanism
RAI-refractory DTC	Sorafenib, Lenvatinib (preferred)	Multikinase inhibitors (VEGFR, RET)
Metastatic MTC	Vandetanib, Cabozantinib	RET + VEGFR inhibitors
ATC + BRAF V600E	Dabrafenib + Trametinib	BRAF + MEK inhibitors

Lenvatinib prolonged PFS by 15.7 months vs placebo (SELECT trial) - important exam fact!

MASTER MNEMONIC: "TRST" (for Differentiated Thyroid Ca)

T → Total Thyroidectomy
R → Radioiodine (RAI) based on risk
S → Suppression of TSH (Levothyroxine)
T → Thyroglobulin surveillance (+ Neck USG)

YOUR EXAM FLASHCARD 🗂️

Management of Thyroid Cancer - High Yield Exam Flashcard

QUICK RECALL SUMMARY TABLE

Feature	PTC	FTC	MTC	ATC
Frequency	80%	10%	5-10%	1%
Spread	Lymphatic	Hematogenous	Lymphatic	Local invasion
Marker	Tg	Tg	Calcitonin + CEA	-
Surgery	Total thyroidectomy	Total thyroidectomy	Total thyroidectomy + CND	Palliative
RAI useful?	Yes	Yes	No	No
Mutation	BRAF V600E	RAS/PAX8-PPAR	RET	BRAF V600E
Prognosis	Excellent	Good	Moderate	Very poor

Sources: Schwartz's Principles of Surgery 11e (Postoperative Management of Differentiated Thyroid Cancer, p.1679-1682); Current Surgical Therapy 14e (Surgical Management section)

This is a shared conversation. Sign in to Orris to start your own chat.